Eton Pharmaceuticals Inc (ETON)vsViatris Inc (VTRS)
ETON
Eton Pharmaceuticals Inc
$55.62
+0.47%
HEALTHCARE · Cap: $1.65B
VTRS
Viatris Inc
$17.62
+0.11%
HEALTHCARE · Cap: $20.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 13856% more annual revenue ($14.74B vs $105.59M). ETON leads profitability with a 12.0% profit margin vs -2.8%. ETON earns a higher WallStSmart Score of 52/100 (C-).
ETON
Buy52
out of 100
Grade: C-
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ETON.
Margin of Safety
-83.9%
Fair Value
$8.77
Current Price
$17.62
$8.85 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.8%
Revenue surging 98.6% year-over-year
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 33.7x book value
ROE of -4.8% — below average capital efficiency
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ETON
The strongest argument for ETON centers on Operating Margin, Revenue Growth. Revenue growth of 98.6% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : ETON
The primary concerns for ETON are Market Cap, P/E Ratio, Price/Book. A P/E of 147.9x leaves little room for execution misses.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ETON profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.90 — expect wider price swings.
ETON is growing revenue faster at 98.6% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
ETON scores higher overall (52/100 vs 48/100) and 98.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?